Clostridium (e.g., Clostridium Tetani, Clostridium Difficile, Clostridium Perfringens, Clostridium Botulinum, Clostridium Chauvoei, Etc.) Patents (Class 424/247.1)
  • Patent number: 9963479
    Abstract: The present invention provides a method for preparing epirubicin and an intermediate adaptive to the method. The preparation method may include: reacting tert-Butyldimethylsilyl chloride with N-trifluoroacetyl adriamycin to obtain a compound of formula I N-trifluoroacetyl-14-O-tert-Butyldimethylsilyl adriamycin; oxidizing the compound of formula I to obtain a compound of formula II 4?-ketone-N-trifluoroacetyl-14-O-tert-Butyldimethylsilyl adriamycin; reducing the compound of formula II to obtain a compound of formula III N-trifluoroacetyl-14-O-tert-Butyldimethylsilyl epirubicin; and performing deprotection and hydrolysis reactions on the compound of formula III to obtain epirubicin. The method of the present invention needs low cost, fewer reaction steps, provides high yield and high product purity, and avoids serious pollution caused by a bromination reaction in a conventional method.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: May 8, 2018
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Wei Yan, Wanzeng Tong, Jianping Wang, Weiqiang Yang, Hongguan Qian
  • Patent number: 9623075
    Abstract: A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin. The method includes administering 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX) to the patient. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation containing a type A1 botulinum toxin.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: April 18, 2017
    Assignee: THE CHEMO-SERO THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Shinji Nakahira, Yasushi Torii, Yoshitaka Goto, Miho Shinmura, Satomi Munechika, Sachio Okuda, Shunji Kozaki
  • Patent number: 9445604
    Abstract: This invention relates to a sterilization agent for livestock bedding or a composting accelerator for organic waste or livestock bedding, comprising at least one Bacillus coagulans thermophilic bacterium or a combination of the at least one Bacillus coagulans thermophilic bacterium and at least one Bacillus subtilis mesophilic bacterium, as an active ingredient, wherein the Bacillus coagulans thermophilic bacterium as a preferable bacterium is viable at a temperature of 40 to 60° C. and the Bacillus subtilis mesophilic bacterium is viable at a temperature of 30 to 50° C., and the mesophilic bacterium also has a sterilizing effect on harmful bacteria in bedding; and to a method for sterilizing livestock bedding or a method for accelerating composting of organic waste or livestock bedding by using these agents each as an active ingredient.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: September 20, 2016
    Assignee: Asahi Calpis Wellness Co., Ltd.
    Inventors: Taisuke Uesugi, Gentaro Yasuda
  • Patent number: 9345729
    Abstract: This invention discloses a method for treating or preventing heart diseases by using a probiotic composition. The method for treating or preventing heart diseases comprises administering to a subject an effective amount of a probiotic composition to prevent the myocardial cells from myocardial hypertrophy, fibrosis and apoptosis, wherein the probiotic composition comprising Lactobacillus rhamnosus LCR177 (BCRC910473), Pediococcus acidilactici PA318 (BCRC910474) and Bifidobacterium adolescentis (BCRC14609).
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: May 24, 2016
    Assignee: NEW BELLUS ENTERPRISES CO., LTD.
    Inventors: Cheng-Chih Tsai, Chih-Yang Huang, Hsueh-Fang Wang, Chun-Hua Chen, Chun-Chih Huang
  • Patent number: 9220783
    Abstract: The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from Clostridium botulinum, the neurotoxin being free of the complexing proteins naturally present in the botulinum neurotoxin complex or being chemically modified or being modified by genetic manipulation. Moreover the pharmaceutical compositions of the instant invention have good stability and are advantageously formulated free of human serum albumin.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: December 29, 2015
    Assignee: MERZ PHARMA GmbH & CO. KGaA
    Inventor: Harold Victor Taylor
  • Patent number: 9199065
    Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: December 1, 2015
    Assignee: Mercator MedSystems, Inc.
    Inventor: Kirk Patrick Seward
  • Patent number: 9139624
    Abstract: An isolated, biologically active 33 kDa hemagglutinin purified from the type A Clostridium botulinum neurotoxin complex and its uses are described.
    Type: Grant
    Filed: May 11, 2009
    Date of Patent: September 22, 2015
    Assignee: Bal Ram Singh
    Inventors: Bal Ram Singh, Shashi Kant Sharma
  • Patent number: 9066894
    Abstract: The present invention provides compounds, compositions, medicaments and methods comprising or using carbohydrate binding molecules. More specifically, the invention provides a means of treating diseases and/or conditions caused or contributed to by pathogens, particularly microbial pathogens and methods of screening, identifying, detecting tagging and/or labelling carbohydrates.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: June 30, 2015
    Assignee: UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS
    Inventors: Helen Connaris, Garry Taylor
  • Patent number: 9060964
    Abstract: Methods are disclosed herein for treating depression in the subject. A method includes the use of Botulinum toxin to cause paralysis of a facial muscle, such as the depressor anguli oris, procerus, frontalis, orbicularis oculi, or corrugator supercilii muscle to treat depression in the subject.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: June 23, 2015
    Inventor: Eric Finzi
  • Patent number: 9050367
    Abstract: The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from Clostridium botulinum, the neurotoxin being free of the complexing proteins naturally present in the botulinum neurotoxin complex or being chemically modified or being modified by genetic manipulation. Moreover the pharmaceutical compositions of the instant invention have good stability and are advantageously formulated free of human serum albumin.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: June 9, 2015
    Assignee: MERZ PHARMA GmbH & CO. KGaA
    Inventor: Harold Victor Taylor
  • Patent number: 9050337
    Abstract: The present invention relates to a pharmaceutical composition for treating scars on the skin, comprising a mixture of botulinum toxin and air. The mixture of botulinum toxin and air according to the present invention, when injected in the dermis, may temporarily removed the elasticity of the dermis and flatten out the depressed part of the scar, and thus enables elaborate intradermic resection and increases the therapeutic effects of lasers for treating pulsed dye laser or of fractional lasers. Thus, scars on the skin can be effectively improved through a one-time operation without negatively affecting the daily lives of patients.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: June 9, 2015
    Inventor: Sang Duck Kim
  • Patent number: 9040036
    Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. Coli, Gemmiger, Desulfamonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: May 26, 2015
    Inventor: Thomas Julius Borody
  • Publication number: 20150143557
    Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
    Type: Application
    Filed: September 22, 2014
    Publication date: May 21, 2015
    Inventors: KENYA HONDA, KOJI ATARASHI, KIKUJI ITOH, TAKESHI TANOUE
  • Publication number: 20150140034
    Abstract: The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals.
    Type: Application
    Filed: September 19, 2014
    Publication date: May 21, 2015
    Inventors: Paul Joseph Dominowski, Dennis L. Foss, Guillermo Gallo, John Morgan Hardham, Richard Lee Krebs, Sandra Ann Marie Lightle, Suman Mahan, Sangita Mediratta, Kaori Mohr, Duncan Mwangi, Sharath K. Rai, Sarah A. Salmon, Shaunak Vora, Lauren Wilmes
  • Patent number: 9028841
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: May 12, 2015
    Assignee: Seres Health, Inc.
    Inventors: Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David A. Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
  • Patent number: 9011879
    Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: April 21, 2015
    Assignee: Mercator MedSystems, Inc.
    Inventor: Kirk Patrick Seward
  • Patent number: 9005628
    Abstract: The present invention is directed to analgesic Clostridial neurotoxin derivatives comprising polypeptides having a long-lasting SNARE protein-selective endopeptidase activity. These derivatives selectively bind to and are internalized by non-neuronal cells secreting cytokines or sensory neurons in preference to motor neurons or autonomic neurons. The invention is also directed to nucleic acid constructs encoding such polypeptides, and methods of making such derivatives and nucleic acid constructs, and methods of treating pain, such as chronic pain, by administering such derivatives to a patient suffering from, or at risk of suffering from such pain.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: April 14, 2015
    Assignee: Dublin City University
    Inventors: James Oliver Dolly, Jiafu Wang, Jianghui Meng
  • Patent number: 9005579
    Abstract: The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.
    Type: Grant
    Filed: January 5, 2011
    Date of Patent: April 14, 2015
    Assignees: Contrafect Corporation, The Rockfeller University
    Inventors: Robert C. Nowinski, Vincent A. Fischetti, Assaf Raz
  • Patent number: 8980283
    Abstract: The present invention describes vaccines that comprise C. perfringens Type alpha toxoids, antigenic fragments thereof, inactivated antigenic fragments of C. perfringens Type alpha toxins, or any combination thereof. The present invention further describes methods of using with these vaccines to protect animals against clostridial diseases. The present invention also describes methods of making these vaccines.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: March 17, 2015
    Assignee: Intervert Inc.
    Inventors: Huchappa Jayappa, Kevin O'Connell
  • Patent number: 8980284
    Abstract: This invention relates to isolated Clostridium botulinum propeptides and neurotoxins, isolated nucleic acid molecules encoding Clostridium botulinum propeptides and neurotoxins, methods of expression, treatment methods, and methods of detecting neurotoxin trafficking. The isolated Clostridium botulinum propeptides have a light chain region; a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond; an intermediate region connecting the light and heavy chain regions and comprising a highly specific protease cleavage site; and an S6 peptide sequence according to SEQ ID NO:2 positioned upstream from, but not attached directly to, the N-terminus of the neurotoxin propeptide at the light chain region to enable site specific attachment of cargo.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: March 17, 2015
    Assignee: New York University
    Inventors: Konstantin Ichtchenko, Philip A. Band
  • Patent number: 8956628
    Abstract: Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of C. perfringens strains. In one embodiment, a purified bacteriophage preparation includes four or more C. perfringens-specific bacteriophage, wherein each bacteriophage has lytic activity against at least five C. perfringens strains. In another embodiment, the purified bacteriophage preparation includes five or more C. perfringens-specific bacteriophage.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: February 17, 2015
    Assignee: Zoetis Products LLC
    Inventors: Jeremy J. Mathers, Alexander Sulakvelidze
  • Patent number: 8920816
    Abstract: A method is provided for treating a neuromuscular defect in a subject. One step of the method includes locating a target nerve. After locating the target nerve, a treatment probe is provided. The treatment probe includes an elongated body member having a proximal end portion and a distal end portion. The distal end portion includes an energy delivery mechanism for stimulating or ablating the target nerve, a monitoring mechanism, and a fluid aspiration/delivery mechanism. Next, the target nerve is verified as an appropriate target for ablation by stimulating and then monitoring the target nerve via the energy delivery mechanism and the monitoring mechanism, respectively. After verifying the target nerve, a tumescent fluid is injected into the tissue surrounding the target nerve. An electric current is then delivered to the energy delivery mechanism to substantially ablate the target nerve.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: December 30, 2014
    Assignee: The Cleveland Clinic Foundation
    Inventor: Francis A. Papay
  • Patent number: 8921322
    Abstract: The present invention relates to the use of at least one botulinum neurotoxin for the production of a medicament for treating or preventing pain induced by a medicament used for treating the AIDS virus.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: December 30, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Christine Favre, Michel Auguet, Pierre-Etienne Chabrier De Lassauniere
  • Patent number: 8900592
    Abstract: The invention relates to a protein construct, comprising (i) a targeting moiety that is capable of binding to a target cell, and (ii) an effector immunogenic moiety that is capable of triggering an existing, vaccine-induced or natural, immune response. The protein construct, that is preferably in the form of a heteromultimeric protein, is useful for redirecting an immune response that was pre-existing in a patient, toward an undesired target cell.
    Type: Grant
    Filed: November 23, 2006
    Date of Patent: December 2, 2014
    Assignee: Universite de Reims Champagne Ardenne
    Inventors: Jacques Henri Max Cohen, Wael Mahmoud, Marcelle Tonye Libyh, Nathalie Godin, Annelise Gimenez, Thierry Tabary, Beatrice Donvito, Daniel Baty, Xavier Dervillez
  • Patent number: 8900597
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: December 2, 2014
    Assignee: Wyeth LLC
    Inventors: Annaliesa Sybil Anderson, Maninder K. Sidhu, Robert G. K. Donald, Kathrin Ute Jansen, Narender Kumar Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
  • Publication number: 20140341974
    Abstract: A vaccine adjuvant composition comprising: a lipid selected from the group consisting of: dipalmitoyl phosphatidicholine (DPPC), dipalmitoyl phosphatidylglycerol (DPPG), dioleoyl phosphatidylcholine (DOPC), and cholesterol and containing a positively or negatively charged lipid with associated/entrapped protein antigen.
    Type: Application
    Filed: March 17, 2014
    Publication date: November 20, 2014
    Inventors: Aryo Sorayya, Mitra Mosharraf, Rajiv Nayar
  • Patent number: 8889151
    Abstract: A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: November 18, 2014
    Assignee: Allergan, Inc.
    Inventors: Catherine C. Turkel, Mitchell F. Brin
  • Patent number: 8883172
    Abstract: The invention provides processes for improving the ability of a peptide to stimulate an immune response, comprising exposing the peptide to a chemical modifying agent. It further provides compositions comprising an antigenic peptide, wherein the peptide has been treated with a chemical modifying agent to improve its ability to stimulate an immune response. It also provides methods of stimulating an immune response in a mammal, comprising administering to the mammal an effective amount of a vaccine.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: November 11, 2014
    Assignee: The Secretary of State for Health
    Inventors: Clifford Shone, Xiaomi Tong, Joanna Clancy, Mili Gu
  • Patent number: 8877208
    Abstract: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods of inducing an immune response against one or a plurality of pathogens (e.g., vaccinia virus, H5N1 influenza virus, Bacillus anthracis, C. botulinum, Y. pestis, Hepatitis B, and/or HIV, etc.) in a subject (e.g., a human subject) and compositions useful in such methods (e.g., immunogenic composition comprising nanoemulsion and one or a plurality of pathogens (e.g., inactivated by the nanoemulsion) and/or pathogen products and/or pathogen components). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: November 4, 2014
    Assignee: The Regents of the University of Michigan
    Inventors: James R. Baker, Jr., Paul E. Makidon, Nicholas J. Mank, Anna U. Bielinska, Luz P. Blanco, Jessica Knowlton
  • Patent number: 8871224
    Abstract: Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: October 28, 2014
    Assignee: Allergan, Inc.
    Inventor: Eric First
  • Publication number: 20140314813
    Abstract: A novel lipoteichoic acid (LTA) was isolated from C. difficile, the structure of which is illustrated below wherein n is an integer between 1 and 20, R3 and R4 are independently selected from C 14:0, C 16:0, C 16:1, C 18:0 or C18:1 fatty acid or any combination thereof wherein one of COR3 or COR4 may be replaced by H. Further described are conjugates comprising the novel LTA and vaccines produced using the isolated LTA and the LTA conjugates. The invention also encompasses methods of conferring immunity against C. difficile comprising administering a vaccine of the invention, and methods of detecting C. difficile using the isolated LTA of the invention.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 23, 2014
    Applicant: National Research Council of Canada
    Inventors: Christopher Reid, Susan M. Logan, Evguenii Vinogradov, Andrew Cox, Jean-Robert Brisson
  • Patent number: 8865177
    Abstract: Methods for treating a pressure sore or for preventing development of a pressure sore by local administration of a Clostridial toxin, such as a botulinum neurotoxin, to a pressure sore or to a pressure point, or to the vicinity thereof.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: October 21, 2014
    Assignee: Allergan, Inc.
    Inventor: Eric R. First
  • Publication number: 20140302094
    Abstract: There is provided a NetB epitope polypeptide comprising at least 10 contiguous amino acids from SEQ ID NO:1 and comprising a mutation in at least one position between amino acids 130 and 297 as compared with the equivalent position in SEQ ID the mutation preferably being located within a rim domain, the polypeptide being capable of binding an antibody which binds to SEQ ID NO:1 and having reduced toxicity compared with the toxicity of SEQ ID NO:1. The polypeptide is useful to vaccinate a subject against infection by Clostridium perfringens.
    Type: Application
    Filed: October 24, 2012
    Publication date: October 9, 2014
    Applicant: UNIVERSITY OF EXETER
    Inventors: Richard W. Titball, Sérgio Paulo Fernandes Da Costa, Claire Naylor, Ajit Basak
  • Patent number: 8853360
    Abstract: An isolated polypeptide comprising a botulinum neurotoxin C1 light chain having a modified amino acid sequence relative to the sequence of a wild-type botulinum neurotoxin C1 light chain is disclosed. The modified botulinum neurotoxin C1 light chain is capable of selectively cleaving syntaxin protein, but has substantially reduced or no activity against SNAP-25 as compared to wild type botulinum neurotoxin C1 light chain, and is thus useful as a research tool and in medical treatment.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: October 7, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Meyer B. Jackson, Dongsheng Wang
  • Patent number: 8852600
    Abstract: In one aspect, the invention provides a DNA molecule. The DNA molecule includes a nucleotide sequence that encodes the receptor-binding domain of Clostridium difficile toxin A or toxin B in which at least about 10% of the in-frame codons for each amino acid residue has a higher percentage use in the human genome than the corresponding in-frame codons of C. difficile toxin A or toxin B having a known sequence. Methods for generating antibodies to Clostridium difficile toxin A or toxin B, methods for reducing the risk of a C. difficile infection, and methods for treating a C. difficile are also provided.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: October 7, 2014
    Assignees: The Rockefeller University, Cornell University
    Inventors: David F. Gardiner, Yaoxing Huang
  • Publication number: 20140294894
    Abstract: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.
    Type: Application
    Filed: April 2, 2014
    Publication date: October 2, 2014
    Applicant: Alba Therapeutics Corporation
    Inventors: Dorothea Sesardic, Blake Paterson
  • Publication number: 20140271718
    Abstract: The subject invention provides compositions for alleviating type 1 diabetes (T1D). In preferred embodiments, the compositions comprise an effective amount of one or more antigen presenting cells (APCs) that have been pulsed with one or more bacterial isolates and/or compounds from the isolates. The bacteria used to pulse the APCs are, preferably, those that confer upon the APCs the ability to inhibit the generation of diabetes-promoting T cells. In specific embodiments, these bacteria may be, for example, Eubacteria or Clostridia. In a preferred embodiment, the APCs are dendritic cells (DCs).
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED
    Inventors: JOSEPH LARKIN, MARK A. ATKINSON
  • Patent number: 8834897
    Abstract: Methods of using tetanus toxin to modulate or control neural functions or nonneural cellular activities at selected sites in animals, particularly in mammals, and more particularly in humans, are provided. Pharmaceutical formulations to modulate neural functions or non-neural cellular activities of an animal at selected sites in animals, particularly in mammals, and more particularly in humans are also provided. Uses of tetanus toxin in preparation of medicaments for methods of treating clinical disorders or symptoms of animals, particularly mammals and more particularly humans are also provided.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: September 16, 2014
    Inventor: Ira Sandars
  • Patent number: 8828945
    Abstract: Treatment and procedures for treating bodily conduits involves deactivating, killing, or otherwise treating smooth muscle tissue of the conduit.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: September 9, 2014
    Assignee: Asthmatx, Inc.
    Inventors: Michael D. Laufer, David C. Auth, Christopher J. Danek, William J. Wizeman, Gary S. Kaplan
  • Patent number: 8784841
    Abstract: The present invention relates to at least one botulinum neurotoxin for treatment of prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: July 22, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Christine Favre, Michel Auguet, Piere-Etienne Chabrier De Lassauniere
  • Publication number: 20140193416
    Abstract: The invention relates to a synthetic oligosaccharide representing part of the repeating unit of the Clostridium difficile glycopolymer PS-I and having the sequence of the pentasaccharide a-L-Rhap-(1?3)-?-D-Glcp-(1?4)-[a-L-Rhap-(1?3]-a-D-Glcp-(1?2)-a-D-Glcp or a synthetic fragment or derivative thereof. Preferably, the claimed synthetic oligosaccharide bears at least one linker L for conjugation to a carrier protein or for immobilization on a surface. Further aspects of the invention relate to advantageous methods for synthesizing said synthetic oligosaccharide and oligosaccharide-protein conjugate as well as to uses thereof, in particular as vaccines and diagnostic tools.
    Type: Application
    Filed: July 30, 2012
    Publication date: July 10, 2014
    Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Peter H. Seeberger, Christopher E. Martin, Felix Broecker, Chakkumkal Anish
  • Patent number: 8747841
    Abstract: The present invention relates to polypeptides transiently activating Ras homolog gene family member A (RhoA) GTPase, polynucleotides encoding said polypeptides and pharmaceutical compositions comprising said polypeptides or said polynucleotides. The present invention further relates to the use of said polypeptides, said polynucleotides or said pharmaceutical compositions for long-term treatment of damage of the peripheral or central nervous system.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: June 10, 2014
    Inventors: Gudrun Ahnert-Hilger, Gisela Groβe, Fred Hofmann, Ingo Just, Markus Höltje, Stefanie Hülsenbeck
  • Patent number: 8747865
    Abstract: Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and related disorders treated by low dose, intramuscular administration of a botulinum toxin.
    Type: Grant
    Filed: January 15, 2013
    Date of Patent: June 10, 2014
    Assignee: Allergan, Inc.
    Inventor: Alan H. Ackerman
  • Patent number: 8728491
    Abstract: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: May 20, 2014
    Assignee: Alba Therapeutics Corporation
    Inventors: Dorothea Sesardic, Blake Paterson
  • Patent number: 8722060
    Abstract: The invention is a method for reducing the symptoms of vertigo. The method is performed by delivering a therapeutically effective amount of presynaptic neurotoxin, such as Botulinum Toxin A, in a pharmaceutically safe form to suitable locations around the head and neck.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: May 13, 2014
    Inventor: William J. Binder
  • Publication number: 20140127263
    Abstract: The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine.
    Type: Application
    Filed: January 15, 2014
    Publication date: May 8, 2014
    Applicant: OmniGen Research, L.L.C.
    Inventors: Neil E. Forsberg, Steven B. Puntenney
  • Patent number: 8715620
    Abstract: A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: May 6, 2014
    Inventor: Ira Sanders
  • Publication number: 20140112951
    Abstract: Disclosed and claimed is a method of non-invasive immunization in an animal and/or a method of inducing a systemic immune response or systemic therapeutic response to a gene product. The skin of the animal is contacted with a non-replicative vector chosen from the group of bacterium, virus, and fungus, wherein the vector comprises and expresses a nucleic acid molecule encoding the gene product, in an amount effective to induce the response.
    Type: Application
    Filed: August 7, 2013
    Publication date: April 24, 2014
    Applicant: UAB RESEARCH FOUNDATION
    Inventors: De-Chu C. Tang, Zhongkai Shi, Kent Rigby van Kampen
  • Patent number: 8697090
    Abstract: A method of controlling dysregulation of the dorsal cutaneous nerve of the clitoris and, in particular, a method for treating PGAD is provided. In one aspect, the method comprises administering a neurotoxin, such as a botulinum toxin, to the clitoral area of the human in need of treatment.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: April 15, 2014
    Assignee: Allergan, Inc.
    Inventor: Marlon P. Rimando
  • Patent number: RE46376
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: April 25, 2017
    Assignee: Wyeth LLC
    Inventors: Annaliesa Sybil Anderson, Robert G. K. Donald, Kathrin Ute Jansen, Michael James Flint